

SUPPORTING INFORMATION

Novel Urea Derivatives as Anti-Tuberculosis Agents

Joshua R. Brown,^a Elton J. North,^a Julian G. Hurdle,^a Christophe Morisseau,^b Jerrod Scarborough,^a Dianqing Sun,^a Jana Korduláková,^c Michael S. Scherman,^d Victoria Jones,^d Anna Grzegorzewicz,^d Rebecca M. Crew,^d Mary Jackson,^d Michael R. McNeil^d and Richard E. Lee^{a}*

^aDepartment of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 1000, Memphis, TN 38105, USA

^bDepartment of Entomology and Cancer Center, University of California, Davis, CA 95616

^c Department of Biochemistry, Faculty of Natural Sciences, Comenius University, Mlynska dolina CH-1, 84215 Bratislava, Slovak Republic

^dMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA

^aDepartment of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 1000, Memphis, TN 38105

^bDepartment of Entomology and UC Davis Cancer Center, University of California, Davis, CA 95616, USA

^c Department of Biochemistry, Faculty of Natural Sciences, Comenius University, Mlynska dolina CH-1, 84215 Bratislava, Slovak Republic

^dMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA

* Author to whom correspondence should be addressed.

REL: Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 1000, Memphis, TN 38105. Tel: (901) 595 6617; Email: Richard.Lee@stjude.org

CONTENTS

RP-HPLC purity and retention times Table S1

Table S2, S3, S4 MIC data for the compounds synthesized against non-tuberculous bacteria








Table S1


Compound #	Rt (M1)	Rt (M2)	% Purity (UV)^a	% Purity ELSD (M1)	% Purity ELSD (M2)
1	6.15		>98%	>98%	
2	6.35		>98%	97%	
3	6.44		95%	96%	
4	6.29		95%	95%	
5	6.39		96%	97%	
6	6.42		95%	95%	
7	6.21		95%	96%	
8	5.88		95%	95%	
9	5.67		95%	95%	
10	6.02		95%	96%	
11	6.12		>98%	>98%	
12	5.98		97%	97%	
13*	5.98	5.27	95%	96%	97%
14	6.39		>98%	>98%	
15	5.73	4.89		96%	97%
16	5.98	5.23		96%	97%
17	5.77	4.91		96%	96%
18	6.14	5.44		96%	96%
19	6.19	5.42		97%	>98%
20	6.33	5.65		>98%	>98%
21	6.48	5.88		>98%	>98%
22	6.56		>98%	>98%	
23	6.37		95%	97%	
24	6.35		>98%	>98%	
25	5.91		95%	95%	
26	6.25		>98%	>98%	
27	6.42		>98%	>98%	

28	6.37		>98%	>98%	
29	6.27		96%	97%	
30	6.12		96%	95%	
31	6.25		>98%	>98%	
32	6.51		>98%	>98%	
33	6.29		>98%	>98%	
34	6.56		>98%	>98%	
35	5.94		>98%	>98%	
36	6.29		>98%	>98%	
37	5.79	4.82		97%	>98%
38	5.69	4.69		96%	96%
39	5.98	5.05		95%	95%
40	6.02	5.13		97%	>98%
41	6.62		95%	97%	

^a Compounds were monitored for UV absorbance at 254 nm wavelength

* Compounds 13 was monitored for UV absorbance at 215 nm wavelength

	24	>200	>200	>200	>200	>200	>200	>200	0.8
	26	>200	>200	>200	>200	>200	>200	>200	25
	30	>200	>200	>200	>200	>200	>200	>200	>200
	27	>200	>200	>200	>200	>200	>200	>200	100
	28	>200	3.12	>200	25	>200	>200	>200	0.4
	29	100	>200	>200	6.25	>200	>200	>200	6.25
	5	>200	3.12	3.12	1.6	>200	>200	>200	0.8



21

>200

>200

>200


>200

>200

>200

>200

1.6



19

>200

>200

>200

>200






>200


>200

>200

12.5

Table S3

Compound	No.	<i>E. fae</i>	<i>B. anthracis</i>	<i>S. aureus</i>	<i>E. coli</i> ToIC	<i>E. coli</i> K12	<i>P. aeruginosa</i>	Klebsiella	<i>M. smeg</i>
	1	>200	>200	>200	>200	>200	>200	>200	1.6
	31	>200	3.12	>200	3.12	>200	>200	>200	NA
	33	>200	>200	>200	25	>200	>200	>200	NA
	34	>200	>200	>200	12.5	>200	>200	>200	200
	32	>200	>200	>200	12.5	>200	>200	>200	50



40

>200

>200

>200


200

>200

>200

>200

200



42

>200

>200

>200

>200

>200

>200

>200

>200

